Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed.
The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of test systems.
OBERON will combine:
Experimental methods: in vitro e.g. on 2D and 3D human-derived cells and tissues, and in vivo i.e. in zebrafish
High throughput omics technologies
Epidemiology and human biomonitoring studies
Advanced computational models: in silico (QSAR, PBPK) and systems biology
OBERON will allow:
To build a mechanistic understanding of toxicity in order to detect ED
To help identifying effective and alternative tests, relevant for human health and in line with regulatory needs
To contribute to the development of novel Adverse Outcome Pathways (AOPs) and AOP networks
OBERON IN NUMBERS
OBERON is a collaborative project funded by the EU Framework Programme for Research and Innovation Action (RIA), Horizon 2020, under Grant Agreement no 825712. With a budget of over 5.9 million €, OBERON started on 1st January 2019 and will last for a duration of 5 years.
Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect EDs-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA).
The direct impacts will be:
- To set up and make available an innovative battery of new, easy to use, effective and validated test systems, combining different experimental and computational strategies, to be used for regulatory aspects regarding ED assessment in relation to metabolic disorders.
- To improve knowledge on EDs based on data generated by OBERON in cell biology, zebrafish, omics technologies and systems biology. Novel mechanistic knowledge will be established, allowing development of novel Adverse Outcome Pathways (AOPs), as well as integration of information in existing AOPs, and identification of novel biomarkers to improve risk assessment frameworks for human health effects.
Partners from 5 EU countries are involved in the project.
The project is coordinated by INSERM :
EURION: A CLUSTER FOCUS ON ENDOCRINE DISRUPTORS
In order to optimize synergies and avoid overlaps between the projects selected for funding from the call SC1-BHC-27-2018 ‘New testing and screening methods to identify endocrine disrupting chemicals’, the projects will form a cluster. It is named EURION for “European Cluster to Improve Identification of Endocrine Disruptors”. This cluster was launched on January 1st 2019.
The OBERON project has started on 1st January 2019
OBERON Kick-Off Meeting took place on the 8st of February 2019 in Brussels, Belgium. This meeting gathered all 11 partners from 6 countries for presenting the planned work program.Continue Reading
Joint Launch Event of Projects
Joint Launch Event of Projects from the Call ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals’ - 31 January, 2019, BrusselsContinue Reading
OBERON Consortium Meetings
- 06 & 07 February 2020: OBERON Annual meeting
- October 2019: Webinar with the International Advisory Panel
- 04 & 05 February 2020: Annual Cluster meeting